Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fraunhofer-Institute of Toxicology and Experimental Medicine
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Physician diagnosis of atopy (allergic rhinitis or mild intermittent asthma)
Age 18-55 years
Nonsmoker (\> 5 years)
Forced expiratory volume in 1 second (FEV1) \> 70% of the predicted value
A positive skin prick test for grass mix or D. pteronyssinus at or within 12 months prior to the screening visit
Informed consent
Females with negative pregnancy test
You may not be if
Infections of the respiratory tract within the last month
Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
Subject is undergoing allergen desensitization therapy
Permanent medication
Systemic or inhaled corticosteroid use within the last month
Anti-inflammatory medication within the last month
Pregnancy
Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment
There is a risk of non-compliance with study procedures
Participation in a clinical trial 30 days prior to enrolment
Clareo Health | Effect of an Immunotoxin on Activated Human Macrophages in Those With Allergic Rhinitis or Mild Intermittent Asthma
